McKenna's Pharmacology for Nursing, 2e

971

Index

aztreonam, 91, 104–105, 122, 123 bacteria and, 91–93 resistance, 94 carbapenems, 90, 97–99 adverse effects, 98 care considerations, 99 contraindications and cautions, 98 drug–drug interactions, 98 pharmacokinetics, 97–98 therapeutic actions and indications, 97 cellular actions, sites, 92 cephalosporins, 90, 99–103 adverse effects, 101–102 calculations, 101 care considerations, 102–103 contraindications and cautions, 101 drug–drug interactions, 102 pharmacokinetics, 101 therapeutic actions and indications, 101 children, 93 fluoroquinolones, 90, 106–108 adverse effects, 106–107 care considerations, 107–108 contraindications and cautions, 106 drug–drug interactions, 107 pharmacokinetics, 106 therapeutic actions and indications, 106 lincosamides, 104, 105–106, 122 adverse effects, 104 care considerations, 105–106 contraindications and cautions, 104 pharmacokinetics, 104 therapeutic actions and indications, 104 macrolides, 91, 103–104, 105–106, 122 adverse effects, 104 drug–drug interactions, 104 drug–food interactions, 104 pharmacokinetics, 103 therapeutic actions and indications, 103 monobactum antibiotic, 104–106, 122 adverse effects, 105 care considerations, 105–106 contraindications and cautions, 105 pharmacokinetics, 105 therapeutic actions and indications, 104 new classes and adjuncts, 121 daptomycin, 121 linezolid (Zyvox), 121 tigecycline, 114, 121 older adults, 93 oral contraceptives and, 115–117 penicillins and penicillinase-resistant antibiotics, 90, 108–111 adverse effects, 110 care considerations, 110–111 contraindications and cautions, 110 drug–drug interactions, 110 care considerations, 105–106 contraindications and cautions, 103–104

education regarding, 111 pharmacokinetics, 109–110 therapeutic actions and indications, 108–109 risks and dangers of antibiotic abuse, 94 sulfonamides, 91, 112–114 adverse effects, 113 care considerations, 113–114 contraindications and cautions, 112 drug–drug interactions, 113 pharmacokinetics, 112 therapeutic actions and indications, 112 tetracyclines, 91, 114–115, 117–118 adverse effects, 115 drug–drug interactions, 115 drug–food interactions, 115 pharmacokinetics, 114 therapeutic actions and indications, 114 Antibodies, 228, 233–234 Anticholinergic agents, 372, 379–381, 501–509, 864, 867, 873–875 adults, 502 adverse effects, 380, 505, 874 care considerations, 381, 507, 874–875 children, 502 contraindications and cautions, 380, 503–505, 874 drug–drug interactions, 380–381, 505–506, 874 heart disease, 508–509 older adults, 502 pharmacokinetics, 380, 503, 873 therapeutic actions and indications, 379–380, 502–503, 873 Anticoagulants, 750, 751, 756–757, 759–764 adjunctive therapy, 751, 757–758, 766 adverse effects, 762 care considerations, 763–764 contraindications and cautions, 762 drug–drug interactions, 762–763 oral therapy, 760–762 pharmacokinetics, 762 therapeutic actions and indications, 760 Antidepressant agents, 316–332 adults, 318 child suicide and, 328 children, 318 depression, 317 biogenic amine theory, 317 care considerations, 117–118 contraindications and cautions, 114–115

monoamine oxidase (MAO) inhibitors, 316, 323–325 adverse effects, 323–324 care considerations, 325 contraindications and cautions, 323 drug–drug interactions, 324 drug–food interactions, 324 pharmacokinetics, 323 therapeutic actions and indications, 323 older adults, 318 pregnancy, during, 318 safe medication administration, 327 selective serotonin reuptake inhibitors (SSRIs), 316, 325–330 adverse effects, 327–328 care considerations, 328–329 contraindications and cautions, 326–327 critical thinking scenario, 329–330 drug–drug interactions, 328 pharmacokinetics, 326 therapeutic actions and indications, 326 tricyclic antidepressants (TCA), 316, 317–322 adverse effects, 321 care considerations, 322 contraindications and cautions, 320 drug–drug interactions, 321–322 pharmacokinetics, 320 therapeutic actions and indications, 317–318, 320 Antidiarrhoeals, 916, 923–926 adverse effects, 924 care considerations, 926 combination products, 923 contraindications and cautions, 924 drug–drug interactions, 924 pharmacokinetics, 923 therapeutic actions and indications, 923 Antidiuretic hormone (ADH), 794, 798 Antiemetic agents, 929–937 5-HT 3 receptor blockers, 929, 931–932, 934–935 adults, 931 care considerations, 936–937 children, 931 dopamine D2 receptor antagonists, 934 older adults, 931 phenothiazines, 929, 930–932, 934 substance P/neurokinin 1 receptor antagonists, 929, 932, 935–936 Antiepileptics, 352, 353, 361–363 critical thinking scenario, 363–365 Antifungal agents, 150–161 adults, 151 children, 151 older adults, 151 pregnancy and breastfeeding, 151 sites of action, 153 systemic, 150, 151–157 azole antifungals, 150, 151–154 care considerations, 156–157 echinocandin antifungals, 150, 152, 154–155

discontinuation syndrome, 321 miscellaneous drugs, 330–331

agomelatine, 330, 331 bupropion, 330, 331 desvenlafaxine, 330–331 mianserin, 331

mirtazapine, 331 moclobemide, 331 reboxetine, 331 selegiline, 331 venlafaxine, 331